GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Marksans Pharma Ltd (BOM:524404) » Definitions » E10

Marksans Pharma (BOM:524404) E10 : ₹4.34 (As of Sep. 2024)


View and export this data going back to 1994. Start your Free Trial

What is Marksans Pharma E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Marksans Pharma's adjusted earnings per share data for the three months ended in Sep. 2024 was ₹2.130. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹4.34 for the trailing ten years ended in Sep. 2024.

During the past 12 months, Marksans Pharma's average E10 Growth Rate was 14.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-12-15), Marksans Pharma's current stock price is ₹312.40. Marksans Pharma's E10 for the quarter that ended in Sep. 2024 was ₹4.34. Marksans Pharma's Shiller PE Ratio of today is 71.98.

During the past 13 years, the highest Shiller PE Ratio of Marksans Pharma was 78.97. The lowest was 13.64. And the median was 21.89.


Marksans Pharma E10 Historical Data

The historical data trend for Marksans Pharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marksans Pharma E10 Chart

Marksans Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 2.89 3.51 4.03

Marksans Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.79 3.90 4.03 4.19 4.34

Competitive Comparison of Marksans Pharma's E10

For the Drug Manufacturers - General subindustry, Marksans Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marksans Pharma's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Marksans Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Marksans Pharma's Shiller PE Ratio falls into.



Marksans Pharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Marksans Pharma's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=2.13/157.8822*157.8822
=2.130

Current CPI (Sep. 2024) = 157.8822.

Marksans Pharma Quarterly Data

per share eps CPI Adj_EPS
201412 0.720 96.780 1.175
201503 0.480 97.163 0.780
201506 0.770 99.841 1.218
201509 0.850 101.753 1.319
201512 0.440 102.901 0.675
201603 -0.140 102.518 -0.216
201606 0.110 105.961 0.164
201609 0.020 105.961 0.030
201612 0.240 105.196 0.360
201703 -0.150 105.196 -0.225
201706 0.330 107.109 0.486
201709 0.230 109.021 0.333
201712 0.410 109.404 0.592
201803 -0.170 109.786 -0.244
201806 0.580 111.317 0.823
201809 0.480 115.142 0.658
201812 0.600 115.142 0.823
201903 0.210 118.202 0.280
201906 0.520 120.880 0.679
201909 0.630 123.175 0.808
201912 0.710 126.235 0.888
202003 1.090 124.705 1.380
202006 1.200 127.000 1.492
202009 1.210 130.118 1.468
202012 1.420 130.889 1.713
202103 1.998 131.771 2.394
202106 1.510 134.084 1.778
202109 1.110 135.847 1.290
202112 1.200 138.161 1.371
202203 0.690 138.822 0.785
202206 1.460 142.347 1.619
202209 1.520 144.661 1.659
202212 1.560 145.763 1.690
202303 1.870 146.865 2.010
202306 1.520 150.280 1.597
202309 1.840 151.492 1.918
202312 1.840 152.924 1.900
202403 1.730 153.035 1.785
202406 1.960 155.789 1.986
202409 2.130 157.882 2.130

Add all the adjusted EPS together and divide 10 will get our e10.


Marksans Pharma  (BOM:524404) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Marksans Pharma's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=312.40/4.34
=71.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Marksans Pharma was 78.97. The lowest was 13.64. And the median was 21.89.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Marksans Pharma E10 Related Terms

Thank you for viewing the detailed overview of Marksans Pharma's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Marksans Pharma Business Description

Traded in Other Exchanges
Address
Veera Desai Extension Road, 11th Floor, Grandeur, Opposite Gundecha Symphony, Oshiwara, Andheri (West), Mumbai, MH, IND, 400053
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.

Marksans Pharma Headlines

No Headlines